119th Congress · introduced in the Senate · Mar 5, 2025
Genomic Data Protection Act
Official title from Congress.gov
Latest action (Mar 5, 2025): Read twice and referred to the Committee on Commerce, Science, and Transportation.
View on Congress.govPolicy area: Commerce
No official summary has been published for this bill.
Includes amendment, cloture, and procedural votes. Each is labeled with its exact question; only a passage question is a vote to pass the bill.
No recorded roll calls on this bill in coverage.
Read twice and referred to the Committee on Commerce, Science, and Transportation.
Introduced in Senate
Actions from Congress.gov, newest first.
LD-2 reports whose issue descriptions explicitly cite this bill (bill type and number validated against Congress.gov records). A citation does not establish the client's position or any contact with a member.
Loading lobbying reportsCoverage: reports for 2025 onward, posted Jan 1, 2025 through Oct 24, 2026.
8 citations.
ANCESTRY · lobbying firm or registrant: KELLEY DRYE & WARREN LLP
2026 Q3 report (Jul 1, 2026 – Sep 30, 2026) · posted Oct 20, 2026 · issue area: Consumer Issues/Safety/Products
$30,000
Paid to lobbying firm
Issues related to federal privacy and data security, particularly as it relates to genetic data; Genomic Data Protection Act (S. 863); KIDS Act (H.R. 7757)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ANCESTRY · lobbying firm or registrant: KELLEY DRYE & WARREN LLP
2026 Q2 report (Apr 1, 2026 – Jun 30, 2026) · posted Jul 20, 2026 · issue area: Consumer Issues/Safety/Products
$30,000
Paid to lobbying firm
Issues related to federal privacy and data security, particularly as it relates to genetic data; Genomic Data Protection Act (S. 863)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ANCESTRY · lobbying firm or registrant: KELLEY DRYE & WARREN LLP
2026 Q1 report (Jan 1, 2026 – Mar 31, 2026) · posted Apr 20, 2026 · issue area: Consumer Issues/Safety/Products
$30,000
Paid to lobbying firm
Issues related to federal privacy and data security, particularly as it relates to genetic data; Genomic Data Protection Act (S. 863)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ANCESTRY · lobbying firm or registrant: KELLEY DRYE & WARREN LLP
2025 Q4 report (Oct 1, 2025 – Dec 31, 2025) · posted Jan 20, 2026 · issue area: Consumer Issues/Safety/Products
$30,000
Paid to lobbying firm
Issues related to federal privacy and data security, particularly as it relates to genetic data; Genomic Data Protection Act (S. 863)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ANCESTRY · lobbying firm or registrant: KELLEY DRYE & WARREN LLP
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Consumer Issues/Safety/Products
$30,000
Paid to lobbying firm
Issues related to federal privacy and data security, particularly as it relates to genetic data; Genomic Data Protection Act (S. 863)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA INC · lobbying firm or registrant: COVINGTON & BURLING LLP
2025 Q3 report (Jul 1, 2025 – Sep 30, 2025) · posted Oct 20, 2025 · issue area: Copyright/Patent/Trademark
$130,000
Paid to lobbying firm
…to biopharmaceutical innovation and intellectual property (no bill); issues related to intellectual property and Bayh-Dole in the Genomic Data Protection Act (S. 863 / no House bill); induced infringement.
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ANCESTRY · lobbying firm or registrant: KELLEY DRYE & WARREN LLP
2025 Q2 report (Apr 1, 2025 – Jun 30, 2025) · posted Jul 21, 2025 · issue area: Consumer Issues/Safety/Products
$30,000
Paid to lobbying firm
Issues related to federal privacy and data security, particularly as it relates to genetic data; Genomic Data Protection Act (S. 863)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing
ANCESTRY · lobbying firm or registrant: KELLEY DRYE & WARREN LLP
2025 Q1 report (Jan 1, 2025 – Mar 31, 2025) · posted Apr 21, 2025 · issue area: Consumer Issues/Safety/Products
$30,000
Paid to lobbying firm
Issues related to federal privacy and data security, particularly as it relates to genetic data; Genomic Data Protection Act (S. 863)
Congress inferred from the report year; bill number and the title cited with it match Congress.gov records, and the bill predates the report. The amount is lobbying spending for every issue on this report, not this bill alone, and none of it is paid to any member of Congress. View filing